Correvio Pharma Corp (CORV_old)

0.4199 0.0000 (0.00%)
Real-time Cboe USD Disclaimer

Correvio Pharma Corp Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
133
Equity Type
ORD
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its products comprise Aggrastat (tirofiban hydrochloride), (an intravenous anti-platelet drug for patients with acute coronary syndrome; and Brinavess (vernakalant IV), a novel, atrial-preferential antiarrhythmic agent for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada. As of May 27, 2020, Correvio Pharma Corp. operates as a subsidiary of Mercury Pharma Group Limited.
Contact Information
Address
Vancouver,V6J 4S7 Canada
Phone
604 677 6905
Fax
604 677 6915

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles